GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » Gross Profit

China NT Pharma Group Co (HKSE:01011) Gross Profit : HK$5.67 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co Gross Profit?

China NT Pharma Group Co's gross profit for the six months ended in Jun. 2024 was HK$6.14 Mil. China NT Pharma Group Co's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was HK$5.67 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. China NT Pharma Group Co's gross profit for the six months ended in Jun. 2024 was HK$6.14 Mil. China NT Pharma Group Co's Revenue for the six months ended in Jun. 2024 was HK$33.69 Mil. Therefore, China NT Pharma Group Co's Gross Margin % for the quarter that ended in Jun. 2024 was 18.23%.

China NT Pharma Group Co had a gross margin of 18.23% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of China NT Pharma Group Co was 80.06%. The lowest was 13.89%. And the median was 62.50%.


China NT Pharma Group Co Gross Profit Historical Data

The historical data trend for China NT Pharma Group Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co Gross Profit Chart

China NT Pharma Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 159.92 178.11 139.91 8.06 5.62

China NT Pharma Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.30 8.06 - 6.14 -0.48

Competitive Comparison of China NT Pharma Group Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China NT Pharma Group Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's Gross Profit falls into.


;
;

China NT Pharma Group Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

China NT Pharma Group Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=8.057 - 0
=8.06

China NT Pharma Group Co's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=33.693 - 27.55
=6.14

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$5.67 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

China NT Pharma Group Co's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=6.14 / 33.693
=18.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


China NT Pharma Group Co  (HKSE:01011) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

China NT Pharma Group Co had a gross margin of 18.23% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


China NT Pharma Group Co Gross Profit Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


China NT Pharma Group Co Business Description

Traded in Other Exchanges
N/A
Address
198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Executives
Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi 2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat 2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines